<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770584</url>
  </required_header>
  <id_info>
    <org_study_id>20-01675</org_study_id>
    <nct_id>NCT04770584</nct_id>
  </id_info>
  <brief_title>Fear and Avoidance in PTSD Patients</brief_title>
  <official_title>Neural Correlates of Active Avoidance Learning and Their Interactions With Fear Extinction Mechanisms in PTSD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to study how the brain learn to avoid certain stimuli&#xD;
      or situations using an experimental paradigm. The big goal is to measure brain responses and&#xD;
      subject's feelings and expectations when they are learning to actively avoid experimental&#xD;
      stimuli, and how fear extinction learning and monetary cost can change how and when subjects&#xD;
      are to avoid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to study the neural correlates of avoidance learning using a recently&#xD;
      validated conditioning and active avoidance paradigm (CAAP). The overarching objective is to&#xD;
      measure the neural correlates of active avoidance, and how fear extinction learning and&#xD;
      monetary cost modulate these avoidance responses. Participants will include trauma-exposed&#xD;
      healthy controls (TEHC), and participants with post-traumatic stress disorder (PTSD).&#xD;
      Avoidance is common and often hinders the progression and success of extinction-based&#xD;
      exposure therapy in PTSD. The data to be gathered in this study will enable us to probe&#xD;
      neural mechanisms of avoidance, extinction, and decision-making to avoid or not, in addition&#xD;
      to understanding the impact of cost on avoidance decision-making. These data will provide a&#xD;
      more integrated platform for the understanding of the mechanisms of avoidance in both&#xD;
      trauma-exposed healthy controls and PTSD psychopathology, which has important implications&#xD;
      for treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Skin Conductance Response (SCR) of PTSD participants and Trauma-Exposed Healthy Controls</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Skin Conductance Response will be collected from subjects during the entire course of the experiment, inside or outside of the fMRI scanner, to measure stress/sweat level. SCR is used by many psychological experiments to measure the participants stress/sweat, or level of anxiety in a particular moment, or in response to a specific cue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of fMRI data of PTSD participants and Trauma-Exposed Healthy Controls</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Participants will undergo a 3T MRI scan during the both experimental. All standard sequences and RF coils which we intend to use at the Center for Brain Imaging are FDA certified.fMRI data will be collected from subjects during the entire course of the 2-day experiment inside the fMRI scanner. fMRI data, including blood-oxygen-level-dependent (BOLD) responses, is used in neuroimaging studies assess neural correlate activations and observe the increase/decrease in activation of a particular brain area in response to a specific cue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>State-Trait Anxiety Inventory STAI (State) The State-Trait Anxiety Inventory (STAI) is a psychological inventory based on a 4-point Likert scale and consists of 40 questions on a self-report basis. The STAI measures two types of anxiety - state anxiety, or anxiety about an event, and trait anxiety, or anxiety level as a personal characteristic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Stress tolerance</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Distress Tolerance Scale (DTS) is a 15 item self-report measure of emotional distress tolerance. Individuals select on a 1-5 likert scale. (Strongly Disagree, Mildly Disagree, Feel Neutral, Mildly Agree, Strongly Agree) about each of the 16 statements about distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in shock expectancy</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Shock expectancy questionnaire is a self reported questionnaire that measures what they expect to see certain colors and whether they expected to feel shocks in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of Pleasantness in Conditioned Stimuli and Unconditioned Stimulus</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Pleasantness Rating of relief scale measures participants sense of the relief they felt when no shock was given, on a scale from 1 to 5 (1=neutral, 5=extremely pleasant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of Unpleasantness in Conditioned Stimuli and Unconditioned Stimulus</measure>
    <time_frame>Experimental Day 1, Experimental Day 2</time_frame>
    <description>Rating of Conditioned Stimuli(CS) and Unconditioned Stimulus (US) Unpleasantness measures participants sense of the unpleasantness they felt when the CS was given, on a scale from 1 to 5 (1=neutral, 5=extremely pleasant)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>PTSD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the initial screening / baseline assessment visit, Post Traumatic Stress Disorder participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trauma-exposed healthy controls (TEHC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After the initial screening / baseline assessment visit, trauma-exposed healthy participants will undergo two Experimental Visits, which included participation in an emotional learning paradigm and an fMRI scan over the course of two consecutive days. Participants will be asked to look at pictures on a computer screen to measure physiological response physiological response (skin conductance response) and brain responses using a functional Magnetic Resonance Imaging (fMRI) machine. These two visits will be scheduled within a month from the baseline assessment visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fear Conditioning</intervention_name>
    <description>Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, &amp; yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color (blue &amp; red - shock; yellow - no shock).</description>
    <arm_group_label>PTSD group</arm_group_label>
    <arm_group_label>Trauma-exposed healthy controls (TEHC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Avoidance conditioning</intervention_name>
    <description>Via button pressing. Only one stimulus-CS (i.e. blue colored light) will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock. CS stays on for 6 seconds after the button is pressed. If the button is pressed, no shock will be administered. After 6 seconds, the light ends and the relief epoch ('good feeling') begins. Pressing the button to the other CS (i.e. red colored light) will not prevent the shock from occurring- the participant will still receive the mild shocked at CS offset (after 6 seconds). The third CS (i.e. yellow light) will serve as a control CS, so while the button is available, pressing it or not is of no consequence.</description>
    <arm_group_label>PTSD group</arm_group_label>
    <arm_group_label>Trauma-exposed healthy controls (TEHC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pavlovian fear extinction learning</intervention_name>
    <description>After avoidance conditioning, the CS+ associated with avoidance responding (i.e. blue light) appears with no button to press and no shock is administered.</description>
    <arm_group_label>PTSD group</arm_group_label>
    <arm_group_label>Trauma-exposed healthy controls (TEHC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Willingness to pay to avoid shock</intervention_name>
    <description>On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. No shocks will be delivered on day 2, regardless of money paid.&#xD;
This and all previously described experimental phases noted above will occur inside of the fMRI scanner.</description>
    <arm_group_label>PTSD group</arm_group_label>
    <arm_group_label>Trauma-exposed healthy controls (TEHC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (PTSD Subjects) :&#xD;
&#xD;
          -  18 - 70 years of age&#xD;
&#xD;
          -  Female or Male&#xD;
&#xD;
          -  Diagnosis of primary PTSD (as determined by SCID)&#xD;
&#xD;
          -  Willing and able to provide informed consent.&#xD;
&#xD;
        Inclusion Criteria (Trauma-exposed healthy controls (TEHC)):&#xD;
&#xD;
          -  18 - 70 years of age&#xD;
&#xD;
          -  Female or Male&#xD;
&#xD;
          -  SCID diagnosis consistent with no current or past history of Axis I psychiatric&#xD;
             disorders.&#xD;
&#xD;
          -  History of trauma exposure.&#xD;
&#xD;
          -  Willing and able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neurologic or psychiatric disease (other than secondary anxiety disorders,&#xD;
             or secondary episodic major depression that is non-psychotic)&#xD;
&#xD;
          -  Current suicidal ideation, plan or intent or suicidal behavior in past 6 months based&#xD;
             on CSSRS or Self-injurious behavior that involves suicidal intent, requires medical&#xD;
             attention, or occurs daily&#xD;
&#xD;
          -  History of seizure or significant head trauma (i.e., extended loss of consciousness,&#xD;
             neurological sequelae, or known structural brain lesion)&#xD;
&#xD;
          -  History of Axis I psychiatric diagnosis; e.g., history of substance use disorder,&#xD;
             psychotic disorder, bipolar disorder, tic disorder, or eating disorder.&#xD;
&#xD;
          -  Use of psychotropic medication within 4 weeks prior to study (within 6 weeks for&#xD;
             fluoxetine, or other long-lived compounds; within one year for neuroleptics).&#xD;
&#xD;
          -  Current substance use (assessed by urine toxicology).&#xD;
&#xD;
          -  Pregnancy (to be ruled out by urine ÃŸ-HCG).&#xD;
&#xD;
          -  Metallic implants or devices contraindicating magnetic resonance imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Milad</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Milad, MD</last_name>
    <phone>646-754-7406</phone>
    <email>Mohammed.milad@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dylan Miller</last_name>
    <phone>646-754-7327</phone>
    <email>Dylan.miller@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dylan Miller</last_name>
    </contact>
    <contact_backup>
      <email>Dylan.Miller@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammed R Milad, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access and give upon reasonable request. Requests should be directed to mohammed.milad@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

